What makes us different

Company Mission

Truly impactful advances in medical development require truly impactful advances in technology and that’s what we’ve tried to do.

Our mission is to build innovative and creative technology that transforms clinical trial processes, empowers and inspires your teams, and puts the power of information and decision-making, not back in your hands, but in your hands. Maybe for the first time.

Why we exist

We want to play our small part in the large ecosystem of clinical teams, pharmaceutical scientists, healthcare professionals, governments and bio-pharmaceutical companies working to bring life-saving therapies to patients worldwide.

Collaboration underpins everything we do at PHARMASEAL, and we recognise it underpins everything out there too.

Who we are

Common sense suggests that the more experts, the better. We agree, but we don’t just want industry experts. We’ve gathered Pharmaseal people from everywhere, which means we have extensive specialisms.

We’re trying to find a solution for the management and control of clinical trials, and that requires a first-rate team. Our people are a talented group of creative software engineers, architects, analysts, experts in agile development, product strategists, and a few industry experts.

To ensure Engility works for you, we want to work with you.

PHARMASEAL Leadership Team

Challenging the Conventional

Daljit Cheema

Founder & CEO

Daljit has 30 years of industry expertise as a technology leader in life sciences. Daljit made key contributions to clinical technology, strategy and development through various managerial roles at PAREXEL International. In 2002, Daljit joined PE-backed Clinphone as CTO. Daljit's pivotal role led to a successful LSE IPO in 2006 and acquisition by PAREXEL in 2008. Following this acquisition, Daljit led Perceptive Informatics, managing 6 global clinical development technology groups. In 2016, Daljit took the entrepreneurial leap and founded PHARMASEAL, driven by a vision to revolutionise technology for the strategic management of clinical trials for companies of all sizes.

Ricky Lakhani

Chief Product Officer

Ricky Lakhani is a product management leader with 17+ years in life sciences and technology and excels in delivering innovative software solutions for clinical trials. His seasoned career encompasses pivotal roles at Amgen, Roche and Medidata where he skillfully navigated the intersection of life sciences and technology, contributing significantly to product innovation and growth. Ricky's commitment to advancing life sciences technology is evident in his influential leadership roles, making him a respected figure in the industry with a track record of delivering cutting-edge and successful technology solutions for the advancement of clinical trial execution.

Hugh O'Neill

Vice President, Quality and Operations

Hugh O’Neill is a PhD Scientist with over 30 years experience in the Pharmaceutical industry, 25 of these in IT roles and 10 years in quality management roles. Hugh has worked for both major global pharmaceutical companies and CROs, developing, implementing, validating, and supporting computer systems, and more recently has been involved in consulting in Quality Management for computer systems. Hugh is a qualified project manager with extensive experience in implementing validated systems, hosting audits and inspections and designing quality management systems. Hugh is also secretary of the RQA IT Committee a global community for QA professionals.

PHARMASEAL Advisors

Guiding our organization

John Young

Advisor

John is an experienced pharmaceutical industry executive with more than 35 years of industry experience. John most recently served as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in 2022. He currently serves on the Boards of Novartis AG (NVTS), Johnson Controls International (JCI), Arvinas Inc (ARVN) and Imbria Pharmaceuticals. He previously served on the Boards of EFPIA (European Federation of Pharmaceutical Industries Associations), BIO (The Biotechnology Innovation Organization) and the National Committee for United States-China Relations.

Wayne R. Kubick

Advisor

Wayne R. Kubick is an executive advisor and expert consultant with more than 30 years of experience in the strategic application of technology to improve clinical research and healthcare. He formerly served as Chief Technology Officer for Health Level Seven International, leading the development of the HL7’s FHIR standard for health data interoperability. His career includes pivotal roles at CDISC and Parexel International, as well as senior positions at Oracle Health Sciences. A key figure in pharmaceutical clinical research, Kubick holds a B.A. from the University of Illinois and an M.B.A. from Boston University.

Karen Roy

Advisor

Karen Roy was jointly responsible for the development of the CDISC TMF Reference Model, an industry driven initiative to standardize the content, naming and structure of Trial Master Files. She chairs the management of the Model – a Model used by the vast majority of Pharmaceutical companies and CROs. She is currently working for CDISC managing the transition of the Model to becoming a CDISC Standard. Karen has also re-joined the Board of the Institute of Clinical Research, a UK-based association focussed on training and being a voice for Clinical Research, and previously was responsible for the development of TMF business at Phlexglobal.